Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Cigna $4.5 billion senior notes offering
The senior notes are due 2029, 2031, 2034 and 2054
Novo Nordisk class certification victory
The district court denied plaintiffs’ motion for class certification in its entirety
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
Greenway Health $375 million refinancing
We advised the administrative agent, arrangers and bookrunners on the financing
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares